What Northern Virginia Owners Should Know in 2026
-
Northern Virginia’s dental M&A market remains active in 2026, with DSOs and private buyers pursuing practices generating $1M+ in annual revenue.
-
EBITDA, or earnings before interest, taxes, depreciation, and amortization, is the primary valuation metric for institutional buyers and reflects true operating profit.
-
Doctor-to-doctor sales can offer a cleaner exit for smaller practices, while DSO affiliation can deliver higher valuations for practices above $1.5M in revenue.
-
Running a structured, competitive bid process, rather than accepting the first offer, often produces higher sale values and better buyer fit.
-
McLerran & Associates provides sell-side representation and side-by-side valuations for Northern Virginia owners; request a free, confidential consultation to explore your options.
Choosing a Sale Path in Northern Virginia
EBITDA Valuation Framework for NoVA Practices
EBITDA, which means earnings before interest, taxes, depreciation, and amortization, represents the operating profit of a practice before financing and tax decisions. Institutional buyers often use EBITDA as the primary metric to price acquisitions. The applicable multiple, or the number used to multiply EBITDA to arrive at enterprise value, can vary based on practice scale, specialty, and buyer type.
Several factors can support higher EBITDA multiples:
-
Clean, normalized EBITDA with defensible add-backs, meaning owner-specific or non-recurring expenses added back to show true profitability
-
Strong hygiene-recall percentage, with 45% or above cited as a benchmark for premium multiples
-
Commercial PPO payer mix of 55% or above
-
Associate depth and low provider concentration, meaning the practice does not depend heavily on one doctor’s production
-
Scalable systems, modern technology, and documented patient retention
Several factors can compress valuations. These can include owner-dentist dependence, where a single doctor produces the majority of revenue, Medicaid payer mix above 40%, and weak hygiene reappointment rates. Practices where the selling doctor produces 90% or more of clinical revenue can receive valuation haircuts, independent of the multiple methodology.
Doctor-to-Doctor vs. DSO: Side-by-Side Comparison
The table below compares doctor-to-doctor sales and DSO or private equity affiliations across several key dimensions, so owners can see how each path may affect valuation, deal structure, and post-close life.
|
Dimension |
Doctor-to-Doctor Sale |
DSO / PE Affiliation |
|---|---|---|
|
Typical valuation basis |
A percentage of annual gross collections; a multiple of SDE for sub-$1M EBITDA practices |
|
|
Valuation premium potential |
Baseline |
|
|
Deal structure |
Primarily cash at close; seller note possible |
Typically a portion of cash at close, rollover equity, earnout component |
|
Post-close work requirement |
Typically a short work-back period |
Typically a multi-year employment agreement |
|
Clinical autonomy post-close |
High; buyer is also a clinician |
Varies by DSO, with standardized protocols and KPIs common |
|
Timeline to close |
Several months |
Six to nine months for many DSOs, up to 18 months for complex platforms |
|
Equity upside (“second bite”) |
Rarely included |
Rollover equity participates in future platform exit |
|
Best fit |
Practices in the $1M–$1.5M revenue range seeking a clean exit |
Practices $1.5M+ revenue seeking higher value and infrastructure support |
Because McLerran & Associates works both paths in roughly equal measure, with an approximately 50/50 split, the firm produces a genuine side-by-side valuation. Owners in the $1.5M–$3M revenue range can compare their worth in both markets before choosing a direction.
Create Competition
The decision to create competition among buyers can be one of the most consequential choices a Northern Virginia practice owner makes. A practice owner who approaches one DSO directly, or who relies on a local broker with limited buyer relationships, often negotiates from a position of significant information imbalance. Dental practices taken to market through a structured multiple-buyer solicitation process receive final sale values above initial unsolicited offers.
McLerran & Associates runs a structured, auction-like bid process that typically lasts 45–60 days and generates multiple offers from a vetted pool of well-qualified buyers. Clients often achieve higher valuations than owners who sell on their own. The range of offers for a single practice continues to widen in 2026, which means the difference between the lowest and highest bid can be substantial, and a competitive process is usually required to capture the top of that range.
Do-it-yourself close rates tend to run lower than a well-run brokered process. McLerran’s transaction rate among its clients is higher than an industry norm. The firm does not just list practices, it focuses on getting them sold.
Contact McLerran & Associates to schedule a confidential discovery call and learn how a structured competitive process could change your outcome in Northern Virginia.
Finding the Right Buyer Fit
The highest bid does not always represent the right buyer. In a market where numerous PE-backed DSOs are operating in the U.S. dental market as of 2026, quality can vary significantly. Buyer type can change not only valuation but also rollover equity, employment terms, diligence burden, integration expectations, closing timing, and seller proceeds. An undercapitalized or poorly managed DSO can put a large share of a seller’s retained equity at risk, including DSOs that later struggle or enter restructuring. In Q1 2026, at least one major DSO engaged a restructuring adviser to address debt from a prior leveraged buyout.
McLerran evaluates buyers using an investment-style lens. Poorly run DSOs are blacklisted and never reach the table. The firm reviews each buyer’s profitability, growth trajectory, management team, and private-equity backing, and helps owners underwrite their rollover equity, meaning the portion of the deal paid in DSO stock rather than cash, as carefully as any investment decision. Up to approximately 40% of a DSO deal can be paid in equity rather than cash, so buyer quality becomes a direct financial consideration, not just a cultural one.
Legacy, staff continuity, and clinical autonomy also form part of the fit equation. McLerran’s mandate is to balance price and fit, securing a strong financial outcome while identifying a buyer whose strategy and support model can help protect what the selling doctor has built.
Maximize Your Outcome
Steps to Sell Your Northern Virginia Dental Practice
-
Begin preparation 12–24 months in advance. Owners who start early can improve financial reporting, reduce owner dependence, stabilize personnel, and defend value during a competitive sale process.
-
Clean and reconcile three years of financials. Organize and reconcile the last three years of tax returns to profit-and-loss statements, run production reports by provider, and calculate real seller’s discretionary earnings.
-
Commission a CPA-led, diligence-grade EBITDA analysis. A free or back-of-the-napkin valuation often becomes the anchor that quietly determines what the owner walks away with. A weak analysis can be re-traded in due diligence, while McLerran’s valuation is built to hold.
-
Receive a side-by-side valuation for both paths. Owners can review their practice’s worth in the private-buyer market and the DSO market before choosing a direction.
-
Go to market through a structured competitive process. McLerran builds a marketing deck and virtual data room, then solicits offers from a vetted pool of buyers over a 45–60-day window.
-
Evaluate offers on total after-tax economics, not headline price. McLerran produces multi-year, multi-structure financial forecasting so owners can compare real cash-in-hand across deal structures and time horizons.
-
Negotiate the LOI with a sell-side advocate. All aspects of the letter of intent, including valuation, cash at close, equity structure, and earnout terms, are negotiated by McLerran on the owner’s behalf.
-
Defend value through due diligence to close. McLerran provides quality-of-earnings defense and reminds buyers that other vetted bidders remain available if they attempt to re-trade the agreed value.
Addressing Common Objections
Information asymmetry: A DSO negotiates deals every week, while a practice owner may sell once in a lifetime. That experience gap means buyers often know exactly how to frame EBITDA, which add-backs will hold, and where to apply pressure during diligence, while most sellers are learning the process for the first time. McLerran levels the table by controlling the narrative around EBITDA and running the deal on the owner’s behalf, so the seller negotiates from a position of closer expertise rather than disadvantage.
Free valuations: The sellers who achieve some of the strongest outcomes often understand their adjusted EBITDA, know how buyers will scrutinize their add-backs, and have already addressed the obvious value-killers before going to market. A free valuation rarely meets that standard.
Buyer vetting: PE-backed dental platforms typically require deeper confirmatory diligence, more rollover equity, tighter legal terms, and greater post-close governance scrutiny than independent DSOs or regional strategic groups. Knowing which buyer type fits a specific practice, and which buyers to avoid, often requires dental-specific expertise that generalist advisors may not provide.
Legacy protection: McLerran’s process narrows from around 10 initial offers to in-person meetings with the top 1–3 finalists. That structure gives owners the information and leverage to choose the buyer who can best protect their patients, staff, and clinical culture.
Conclusion
Northern Virginia’s dental M&A market in 2026 remains active, well-capitalized, and continues to move toward greater consolidation. A significant percentage of buyers have indicated they expect to complete a recapitalization within the next 12 to 36 months, which can create a meaningful seller’s window for owners of healthy, premier practices. That window tends to favor prepared sellers with professional representation rather than those who go it alone or accept the first offer on the table.
McLerran & Associates has guided numerous practice sales totaling substantial closed transaction volume over approximately 35 years. The Northern Virginia office, led by Andrew Kobylski, brings that depth of dental-specific, sell-side expertise to owners across the NoVA market, from Arlington and Fairfax to Manassas and surrounding communities.
Ready to explore a transition? Schedule a free, confidential discovery call with McLerran & Associates by calling (512) 900-7989 or visiting the contact page at dentaltransitions.com. You can also reach the team directly at info@dentaltransitions.com.
Not ready to sell yet? Join the McLerran M&A Summit (October 29–30, 2026), a dental-only event built for owners who have not decided yet. Attendees earn 4 CE credits and receive a complimentary practice valuation, a $2,500 value. Learn deal structures, EBITDA fundamentals, and the DSO landscape before committing to anything. Reserve your seat at dentaltransitions.com/summit or call (512) 900-7989 for details.
Frequently Asked Questions
How is a Northern Virginia dental practice valued in 2026?
Valuation method can depend on the buyer type and the path being pursued. In a doctor-to-doctor sale, practices are often valued as a percentage of annual gross collections or a multiple of seller’s discretionary earnings, which means the practice’s true cash flow to the owner-operator. In a DSO or private-equity transaction, the primary metric is EBITDA, and the applicable multiple can vary based on practice scale, specialty, payer mix, associate depth, hygiene program strength, and how dependent the practice is on the selling doctor’s personal production. Practices with clean, normalized EBITDA, strong hygiene recall, and low owner dependence tend to attract some of the most competitive offers. McLerran’s CPA-led valuation process unpacks every add-back and builds a defensible number before going to market, so the agreed value has a better chance of holding through due diligence rather than being re-traded by the buyer.
Should I sell to a private buyer or affiliate with a DSO?
The right path can depend on your practice’s size, profitability, and your personal goals. Smaller premier practices, generally in the $1M–$1.5M revenue range, often fit a doctor-to-doctor sale, which can offer a cleaner exit with a shorter transition period. Larger practices, particularly those above $1.5M in revenue, may qualify for DSO or private-equity affiliation, which can deliver a higher valuation based on EBITDA multiples rather than collections percentages. Practices in the $1.5M–$3M revenue range can often qualify for both paths. Because McLerran works both markets in roughly equal measure, the firm produces a side-by-side valuation so owners can compare their worth and projected after-tax proceeds on each path with fuller information rather than a guess. The answer is specific to your practice, which is why a discovery call can be a practical starting point.
What makes Northern Virginia an active market for dental practice sales?
Northern Virginia’s dental market can be attractive to institutional buyers for several reasons. The region includes a high-income, commercially insured patient base across many communities, strong population density and growth in corridors like Arlington, Fairfax, and the outer suburbs, and proximity to a large, educated workforce that supports premium dental services. These characteristics can support favorable payer mix and hygiene economics, two of the factors buyers often weigh heavily when reviewing a practice. DSO and private-equity buyers have shown active interest in the NoVA market through documented affiliations and new practice openings in 2026. For owners of premier practices, that buyer demand can create the competitive environment that a structured sell-side process is designed to capture.
How long does it take to sell a Northern Virginia dental practice?
Timeline can vary by path. A doctor-to-doctor sale typically takes 4–6 months from engagement to closing. A DSO or private-equity transaction often runs 6–9 months, and more complex platform-level deals can extend to 18 months because of multi-layer due diligence and multi-document legal structures. McLerran’s competitive bid process, the phase where offers are solicited and evaluated, typically runs 45–60 days. Preparation before going to market forms a separate and important phase. Owners who begin 12–24 months in advance can address value-killers, clean financials, and reduce owner dependence before buyers scrutinize the practice. If you are not ready to sell today, McLerran can update your valuation for free a year later rather than push you into a deal before the timing feels right.
What does McLerran & Associates charge, and what does the process include?
McLerran charges for its valuation work, which creates a clear distinction from firms that offer free valuations as a lead-generation tool. A paid, CPA-led valuation represents diligence-grade work done up front, so the number has a better chance of holding when buyers scrutinize it and the deal is less likely to be re-traded. From there, the full engagement can cover the EBITDA analysis, financial forecasting across deal structures and time horizons, marketing deck and virtual data room preparation, confidential buyer outreach, the competitive bid process, LOI negotiation, quality-of-earnings defense through due diligence, and advocacy through closing. The firm is sell-side only and never represents the buyer, so its incentives remain aligned with the selling doctor’s outcome. Specific fee structures are discussed during the discovery call, where Andrew Kobylski can walk through what the process might look like for your specific practice and goals.
